Inspira Technologies Oxy BHN Ltd (IINN)

[subslover]

Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections
The ex-vivo testing demonstrated significant bacterial reduction for the innovative IV dressing technology aimed at preventing bloodstream infections in critical patients

RA'ANANA, Israel, Feb. 11, 2025 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in breakthrough life-support technology, today announced positive initial results from its previously reported collaboration with Ennocure MedTech Ltd. to develop a novel bio-electronic treatment for preventing bloodstream infections.



https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg


In ex-vivo porcine skin model testing, the bio-electronic patch demonstrated a 95% reduction in bacterial presence within 4 hours, with continued effectiveness observed over a 24-hour period. The technology, which uses physical electric stimulation rather than chemical agents, showed promising results in preventing pathogen growth on treated surfaces.

"We believe that these initial results represent an important milestone in our development of next-generation infection prevention technology," said Dagi Ben-Noon, CEO of Inspira. "With an estimated 250,000 bloodstream infections related to intravenous lines occurring worldwide each year, we believe this novel approach could potentially offer significant advantages in critical care settings."

The bio-electronic technology is being designed to address several key challenges associated with traditional IV dressings, including:

Prevention of bacterial growth through physical rather than chemical means
Potential for extended wear time, reducing frequency of dressing changes
Applicability to both skin surface and cannula areas
Real-time monitoring capabilities
Testing was conducted following adjusted standardized protocols, including the AATCC TM100 standard for antimicrobial performance, with results showing consistent bacterial reduction under active patches compared to controls.